Clinical Significance of the TP53 Co-Mutation in EGFR-Mutant NSCLC

Dr. Gumbleton discusses the clinical significance of Mrs. Chen's TP53 R248W pathogenic co-mutation. He notes that TP53 co-mutations are common in EGFR-mutated NSCLC—a ballpark estimate of at least half of cases—and that their biological significance is real rather than theoretical.

Patients with TP53 co-mutations typically experience a more aggressive disease course. They respond less durably to front-line therapy, they progress earlier, and they do not achieve as deep a response on tyrosine kinase inhibitor (TKI) monotherapy compared with patients who do not harbor a TP53 alteration. For Dr. Gumbleton, this is a strong reason to favor a combination regimen in this case and steers him away from osimertinib monotherapy.

A second consideration he highlights is CNS risk. Patients with TP53 co-mutations have a higher risk of progression in the brain, and CNS progression carries significant quality-of-life implications when it occurs. Given Mrs. Chen's stated goal of maximizing her expected survival and the added CNS risk conferred by TP53, Dr. Gumbleton notes this pushes the decision even more firmly toward a combination front-line regimen, narrowing the viable options from three down to two.

In the next episode, “Choosing Between MARIPOSA and FLAURA2: Efficacy Data Side by Side”, Dr. Gumbleton compares the two preferred combination regimens in the absence of a head-to-head trial.